Anzeige
Mehr »
Mittwoch, 04.02.2026 - Börsentäglich über 12.000 News
Revolutionäre Entwicklung im Megatrend - Der KI-Durchbruch für Pflege und Sicherheit!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N6NC | ISIN: US6827361030 | Ticker-Symbol: ON40
Siehe auch ONO PHARMACEUTICAL CO LTD
München
04.02.26 | 09:01
4,580 Euro
+14,50 % +0,580
Branche
Pharma
Aktienmarkt
JAPAN
1-Jahres-Chart
ONO PHARMACEUTICAL CO LTD ADR Chart 1 Jahr
5-Tage-Chart
ONO PHARMACEUTICAL CO LTD ADR 5-Tage-Chart
RealtimeGeldBriefZeit
4,2804,52015:10

Aktuelle News zur ONO PHARMACEUTICAL CO LTD ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoOno Pharmaceutical GAAP EPS of ¥146.07, revenue of ¥397.04B; reaffirms FY outlook3
MoOno Pharmaceutical Co. Ltd. Reveals Climb In Nine Months Bottom Line225TOKYO (dpa-AFX) - Ono Pharmaceutical Co. Ltd. (OPHLF) released a profit for its nine months that Increases, from the same period last yearThe company's earnings came in at JPY68.949 billion...
► Artikel lesen
ONO PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln
26.01.Ono Pharmaceutical stock initiated with Buy rating at UBS on ONO-4578 potential2
26.01.Ono Pharmaceutical: UBS startet Coverage mit Kaufempfehlung - Pipeline-Kandidat ONO-4578 im Fokus6
14.01.Ono Pharma Taiwan Receives Additional Approval Of Opdivo In Combination With Ipilimumab251BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Ono Pharmaceutical Co. announced that Ono Pharma Taiwan Co., a Taiwanese subsidiary of Ono, received the additional approval of Opdivo Intravenous Infusion...
► Artikel lesen
30.10.25Ono Pharmaceutical reports Q2 results8
30.10.25Ono Pharmaceutical H1 Results Improve; Backs Annual Guidance363TOKYO (dpa-AFX) - Ono Pharmaceutical Co., Ltd.(OPHLF, 4528.T) on Thursday reported a rise in earnings and revenue for the first half. In addition, the company has reaffirmed its annual outlook.For...
► Artikel lesen
09.10.25Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test25
01.08.25Ono Pharmaceutical Co. Ltd. Reports Retreat In Q1 Bottom Line685WASHINGTON (dpa-AFX) - Ono Pharmaceutical Co. Ltd. (OPHLF.PK) revealed earnings for first quarter that Drops, from the same period last yearThe company's earnings totaled JPY17.673 billion,...
► Artikel lesen
04.03.25DelveInsight Business Research, LLP: Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight1.118On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places...
► Artikel lesen
04.03.25DelveInsight Business Research, LLP: Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight1.225On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places...
► Artikel lesen
11 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1